The ability of nanomedicines to navigate the body’s complexities provides an edge against metastasis. Metastasis involves a series of steps, wherein cancer cells travel from their original site to establish secondary tumors. Each of these stages presents unique therapeutic targets for intervention. Recent investigations reveal that nanomedicine can disrupt these processes through various mechanisms, thereby impeding the progression of metastatic disease. Targeting cancer cell invasion is crucial; the early interactions between cancer cells and the surrounding extracellular matrix can be hindered by nanoparticles designed to inhibit proteolytic enzymes or modulate adhesive interactions critical for invasion.

Intravasation—the entry of cancer cells into the bloodstream—is another critical step in metastasis, often facilitated by the breakdown of blood vessel barriers. Studies have demonstrated how certain nanocarriers are engineered to enhance drug delivery, targeting pathways essential for this process. By utilizing nanoparticles that selectively release therapeutics in response to the unique microenvironment of the tumor, it is possible to diminish the likelihood of cancer cells entering circulation, thus reducing the potential for metastatic spread.

Once in circulation, cancer cells face various physical challenges, including shear stress from blood flow and immune system detection. Nanomedicine offers the potential to camouflage these cells, enabling them to evade immune surveillance and survive longer in the bloodstream. Furthermore, the design of nanoparticles is continually evolving; researchers are exploring stimuli-responsive systems that can release therapeutics upon encountering specific microenvironmental signals, thus ensuring enhanced efficacy.

As cancer cells extravasate from the bloodstream to establish new sites of growth, the response of the endothelium plays a significant role. Targeting the interactions between circulating cancer cells and the endothelial cells of blood vessels is pivotal for successful colonization. Here, nanomedicines can be tailored to inhibit adhesion molecules which these cells utilize, ultimately restricting their ability to leave the circulation and invade new tissues. This targeted approach can ultimately prevent the formation of secondary tumors and enhance patient outcomes.

In addition to targeting the steps of metastasis, active targeting features of nanomedicine offer opportunities for personalized therapeutics. By equipping nanoparticles with ligands that bind to specific receptors overexpressed in metastatic sites, the precision of treatment can be drastically improved. This form of active targeting aids in minimizing collateral damage to healthy tissues, thus reducing side effects and improving the overall therapeutic index.

The potential of multidrug combinations using nanomedicine has also been a focal point in research endeavors. Combining chemotherapeutic agents with nanoparticles that can co-deliver multiple drugs could simultaneously inhibit different metastatic pathways. This multi-faceted approach could pave the way for synergistic effects that enhance the overall effectiveness of treatment, addressing the multifactorial nature of cancer metastasis.

Moreover, nanomedicine plays a significant role in RNA delivery for antimetastatic therapies. The potential for RNA-based therapeutics, such as RNA interference (RNAi), offers a novel method for silencing genes implicated in metastasis. Nanoparticles can facilitate the delivery of these RNA molecules directly to target cells, improving the possibility of a successful treatment outcome. Given the complexity of gene regulation in cancer, this platform may offer a glimpse into the future of personalized medicine, where patients could receive tailored therapies based on genetic profiling.

Immunotherapy has evolved as a cornerstone of cancer treatment, and nanomedicine is poised to enhance its efficacy. Nanoparticles can serve as vehicles for immunomodulatory agents, helping to prime the immune system for attack against metastatic tumors. Innovative designs that focus on stabilizing immune checkpoint inhibitors or stimulating immune cells can be integrated into nanoparticle formulations. The synergy between nanomedicine and immunotherapy holds great promise for improving the long-term management of metastatic cancer.

Patient stratification is essential in the clinical testing and translation of antimetastatic nanomedicines. The heterogeneity of tumors means that not every patient will respond to the same treatment. By employing biomarkers to identify patients who are likely to benefit from specific nanomedicine approaches, healthcare providers can tailor interventions more effectively. This precision medicine approach has the potential to enhance treatment responses and improve survival rates, paving the way for more successful therapeutic regimens.

While the landscape of antimetastatic nanomedicines is promising, significant milestones must be addressed before these therapies can become mainstream. Rigorous preclinical studies, clinical trial designs, and regulatory pathways must be navigated to ensure safe and effective treatments reach patients. Ongoing research in this realm is critical, as it provides the data necessary to substantiate the efficacy of these innovative therapies and ultimately leads to improved cancer management strategies.

The future of antimetastatic nanomedicine is bright, bolstered by continuous advancements in technology and a deeper understanding of cancer biology. As researchers unravel the complexities of the metastatic cascade and refine the design of nanomedicines, there exists tremendous potential to shape the next generation of cancer therapies. By targeting metastasis in a multifactorial manner, we can move toward a future where cancer treatment not only aims to eradicate primary tumors but also ensures that metastatic disease does not take hold, offering hope to countless patients around the globe.

In conclusion, as the field of nanomedicine continues to evolve, it becomes increasingly clear that its integration into cancer therapy represents a paradigm shift in how we approach metastatic disease. Through innovative formulations and strategic targeting, nanomedicines hold the promise of transforming treatment outcomes and enhancing our ability to combat one of the most insidious aspects of cancer.

Subject of Research: Nanomedicine targeting metastatic cancer

Article Title: Targeting metastasis with nanomedicine

Article References:

Pallares, R.M., Consolino, L., Wang, A. et al. Targeting metastasis with nanomedicine.
Nat Rev Bioeng (2025). https://doi.org/10.1038/s44222-025-00358-7

Image Credits: AI Generated

DOI: 10.1038/s44222-025-00358-7

Keywords: Nanomedicine, metastatic cancer, drug delivery, tumor microenvironment, immunotherapy, RNA delivery, patient stratification, antimetastatic therapy.

For decades, tumor necrosis has been largely viewed as a passive consequence of unchecked tumor growth, associated with hypoxia and nutrient deprivation. However, the current findings challenge this dogma, demonstrating that pleomorphic necrosis within the primary tumor is an orchestrated event driven by immune cell-mediated vascular occlusion. Central to this process are low Ly6C-expressing neutrophils, which reside predominantly within the blood vessels and possess a greater propensity to form NETs. These NETs — networks of decondensed chromatin studded with antimicrobial proteins — physically obstruct the microvasculature, precipitating ischemic damage and subsequent necrosis.

To decode this mechanism, the researchers employed an elegant genetic model by generating mice deficient in protein-arginine deiminase 4 (PAD4) specifically in neutrophils. PAD4 is an essential enzyme for NET formation, catalyzing citrullination of histones that unfurls chromatin into extracellular webs. Mice lacking PAD4 in their neutrophils (referred to as PAD4^ΔN) provide a clean canvas to dissect the contribution of NETs within tumorigenesis. Upon transplantation of Lewis lung carcinoma (LLC) cells into these mice, a striking contrast emerged: while tumors formed in both PAD4^ΔN and wild-type (PAD4^WT) mice, those in PAD4^ΔN mice exhibited markedly diminished vascular damage, near-complete absence of citrullinated NETs, and significantly reduced necrotic regions.

The implication is profound — NET formation is a driving force behind the necrotic architecture of tumors, refuting the notion that necrosis arises solely from hypoxia or tumor overgrowth. Detailed imaging revealed that in wild-type mice, neutrophil-rich areas within tumors coincided with substantial microvascular loss, evidenced by decreased CD31 staining of endothelial cells, whereas PAD4^ΔN mice retained intact vasculature in these regions. This finding firmly links NET-mediated vascular occlusion to ensuing tissue destruction.

Crucially, the biological ramifications of NET blockade extended beyond local tumor pathology to impact metastatic dissemination. The primary tumors formed in PAD4^ΔN mice gave rise to significantly fewer lung metastases both in terms of total metastatic burden and the number of metastatic foci. Intriguingly, the size of individual metastatic lesions remained comparable between genotypes, indicating that the defect lay not in the growth capacity of seeded cancer cells but in the capacity of tumor cells to exit the primary site. This was further corroborated with intravenous injection models where cancer cells already present in the bloodstream generated similar metastatic loads regardless of PAD4 status, highlighting the crucial role of NETs in tumor cell egress.

Complementary approaches to interfere with NET formation cemented the causal link between NETs and tumor progression. Treatment of tumor-bearing mice with DNase I, an enzyme degrading extracellular DNA structures, recapitulated the phenotype observed in PAD4-deficient models: reduced tumor necrosis and fewer metastatic lesions. This reinforces the notion that therapeutic targeting of NETs might represent a viable strategy to mitigate cancer spread.

Pushing the translational envelope, the researchers explored the effects of disulfiram — an FDA-approved drug historically used for alcohol aversion therapy — recently recognized for its capacity to inhibit NET formation in lung injury models. Disulfiram treatment in a 4T1 breast cancer model resulted in diminished NET presence within tumors, reduced necrosis, and a striking reversal of pro-metastatic molecular signatures typically observed in necrotic tumors. Notably, this intervention curtailed lung metastases without affecting primary tumor growth, suggesting that targeting NETs disarms dissemination rather than tumor proliferation.

At the molecular dimension, RNA sequencing of cancer cells isolated from necrotic versus non-necrotic tumors unveiled that the presence of necrosis imparts a profound transcriptomic reprogramming. Tumor cells exposed to necrotic environments upregulated gene pathways related to hematopoiesis, epithelial-to-mesenchymal transition (EMT), enhanced migratory capacity, metabolic adaptation, and programmed cell death. EMT markers such as increased vimentin and decreased E-cadherin were markedly elevated in cancer cells in necrotic regions of PAD4^WT tumors but absent in PAD4^ΔN counterparts, underscoring the influence of the pro-necrotic milieu in fostering metastatic attributes.

These insights collectively paint a picture of neutrophils as double-edged swords within the tumor microenvironment. While conventionally appreciated for their antimicrobial roles, neutrophils — through NET release — contribute to a pathological cascade culminating in vascular occlusion, tumor tissue breakdown, and enhanced metastatic propensity. The identification of PAD4-mediated NET formation as a critical node in this process offers a precise molecular target for drug development.

The translational potential of these findings is immense. By intercepting NET formation — via PAD4 inhibition, enzymatic NET degradation, or repurposing agents like disulfiram — clinicians might be able to prevent the formation of necrotic, pro-metastatic niches within tumors. Such strategies could complement existing therapies, aiming to disrupt the early steps of metastasis, often the lethal phase of cancer progression.

Future work will need to validate these mechanisms across diverse tumor types and clinical settings. Additionally, deciphering the interplay between various neutrophil subsets, the vascular endothelium, and cancer cells may uncover further layers of regulation. Understanding how NETs influence immune evasion, angiogenesis, and the pre-metastatic niche will be pivotal in harnessing their pathological roles for therapeutic gain.

This study redefines tumor necrosis not as a passive hallmark but as an active, immune-driven process with tangible implications for metastasis. It highlights the complexity of tumor-immune cross-talk and propels NETs from a relatively obscure feature to a central axis of cancer biology. As research expands on these revelations, the prospect of NET-targeted therapies offers hope for reducing metastatic disease and improving patient outcomes.

The cell biology community and oncologists alike should take heed: neutrophils, far from mere first responders to infection, wield a potent influence on tumor fate. Unraveling the mechanistic underpinnings of NET-mediated vascular occlusion charts a promising roadmap for innovative cancer treatments, turning our immune cells’ weapons against cancer’s devastating progression.

Subject of Research: The role of neutrophil extracellular traps (NETs) in vascular occlusion, tumor necrosis, and metastasis in cancer.

Article Title: Neutrophils drive vascular occlusion, tumour necrosis and metastasis.

Article References: Adrover, J.M., Han, X., Sun, L. et al. Neutrophils drive vascular occlusion, tumour necrosis and metastasis. Nature (2025). https://doi.org/10.1038/s41586-025-09278-3

Image Credits: AI Generated